Merck reported a robust first quarter with strong sales growth and raised its non-GAAP EPS guidance, reflecting confidence in its pipeline and strategic initiatives like the VICTRELIS approval and a significant share buyback program. The positive management tone and effective cost control measures are likely to bolster investor sentiment in the short term.

[1]